<?xml version="1.0" encoding="UTF-8"?>
<p>As a prophylactic measure and therapy, monoclonal and polyclonal antibodies (targeting hemagglutinin binding) have been recommended to treat various viral infections including influenza (Beigel et al., 
 <xref rid="B16" ref-type="bibr">2019</xref>). The effectiveness of these antibodies against MERS-CoV largely encouraged the recent efforts to develop monoclonal and polyclonal antibodies against coronaviruses (Sheahan et al., 
 <xref rid="B164" ref-type="bibr">2017</xref>). For instance, in a phase I trial, SAB-301 (a human polyclonal antibody) which was produced in transchromosomic cattle was found to be safe and better tolerated in healthy participants (Beigel et al., 
 <xref rid="B16" ref-type="bibr">2019</xref>). In a study, Cockrell et al. (
 <xref rid="B49" ref-type="bibr">2016</xref>) revealed in mouse models that human monoclonal antibodies (mAbs)-based immunotherapy only mediated protection in the early stage of MERS (Martinez, 
 <xref rid="B124" ref-type="bibr">2020</xref>).
</p>
